Screener
Nurix Therapeutics, Inc. NRIX Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026.
- Filed
- Jul 9, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001549595-26-000040
| Line item | May 31,2026 | November 30,2025 |
|---|---|---|
| Accounts payable | $12,208 | $11,215 |
| Accrued expenses and other current liabilities | 43,267 | 54,852 |
| Operating lease liabilities, current | 3,221 | 2,824 |
| Deferred revenue, current | 13,324 | 17,580 |
| Total current liabilities | 72,020 | 86,471 |
| Operating lease liabilities, net of current portion | 54,922 | 52,906 |
| Deferred revenue, net of current portion | 5,971 | 10,011 |
| Total liabilities | 132,913 | 149,388 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Nurix Therapeutics, Inc.'s deferred revenue?
- Nurix Therapeutics, Inc. (NRIX) reported deferred revenue of $13.32M in Q1 2026.
- How has Nurix Therapeutics, Inc.'s deferred revenue changed year-over-year?
- Nurix Therapeutics, Inc.'s deferred revenue decreased by 51.4% year-over-year, from $27.42M to $13.32M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s deferred revenue?
- Over 5 years (2020 to 2025), Nurix Therapeutics, Inc.'s deferred revenue has grown at a -11.7% compound annual growth rate (CAGR), from $32.8M to $17.58M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Nurix Therapeutics, Inc.'s deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude